Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Since 13 November 2013, XOFIGO has been authorised on the European zone for the treatment of patients with prostate cancer, in the phase of resistance to castration, with symptomatic bone metastases.
bone metastases frequently give rise to "bone events" that include spinal cord compressions and pathological fractures requiring surgery or external radiotherapy.
Bone metastases are an important cause of death, disability, quality of life degradation and increase the cost of treatment.
Xofigo is indicated in patients with bone metastases symptomatic of hormone-resistant prostate cancer and without known visceral metastases.
Since 13 November 2013, XOFIGO has been authorised on the European zone for the treatment of patients with prostate cancer, in the phase of resistance to castration, with symptomatic bone metastases. Prostate cancer is the most common non-cutaneous cancer in men internationally, and more than 90% of patients with hormone-resistant prostate cancer will have bone metastases.
They frequently give rise to "bone events" that include spinal cord compressions and pathological fractures requiring surgery or external radiotherapy.
Bone metastases are an important cause of death, disability, quality of life degradation and increase the cost of treatment.
There is therefore a need for bone-targeting therapeutic agents that provide a benefit in terms of survival.
Xofigo is indicated in patients with bone metastases symptomatic of hormone-resistant prostate cancer and without known visceral metastases.
This treatment appears to have fewer side effects than chemotherapy (and does not call into question subsequent chemotherapy) or that the currently available metabolic bone radiotherapy as well as better pain control and survival gain than the latter do not
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| clinical database | Other | The various clinicam database will be collected solely to meet the objectives of the study. All data collected to create the database for this project will be anonymized |
| Measure | Description | Time Frame |
|---|---|---|
| Assess the epidemiological characteristics of the treated patient population | clinical data collection in the medical record | during the treatment of XOFIGO an average of 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Assess the presence of adverse events resulting from short-term and medium-term XOFIGO treatment | clinical data collection in the medical record | during the treatment of XOFIGO an average of 24 weeks |
| Assess the number of patients who were able to benefit from the complete treatment (6 cycles) |
Not provided
Inclusion Criteria:
All patients who received treatment with XOFIGO in the framework of the AMM, in France since November 2013 are potentially eligible.
Exclusion Criteria:
Patients expressing a refusal to use this research data
Not provided
Not provided
Not provided
All patients who received treatment with XOFIGO in the framework of the AMM, in France since November 2013 are potentially eligible.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emmanuel DESHAYES, MD | ICM Val d'Aurelle | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Icm Val D'Aurelle | Montpellier | Herault | 34298 | France | ||
| ICO Bordeaux |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23326203 | Result | Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5:1-14. doi: 10.2147/CMAR.S25537. Epub 2013 Jan 8. | |
| 22341993 | Result | Nilsson S, Strang P, Aksnes AK, Franzen L, Olivier P, Pecking A, Staffurth J, Vasanthan S, Andersson C, Bruland OS. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012 Mar;48(5):678-86. doi: 10.1016/j.ejca.2011.12.023. Epub 2012 Feb 15. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
clinical data collection in the medical record |
| during the treatment of XOFIGO an average of 24 weeks |
| Collect the causes of premature discontinuation of treatment | clinical data collection in the medical record | during the treatment of XOFIGO an average of 24 weeks |
| assess the antalgic effet of treatment (number of antalgic taken and how many time) | clinical data collection in the medical record | during the treatment of XOFIGO an average of 24 weeks |
| assess the overall survival | clinical data collection in the medical record | during the treatment of XOFIGO an average of 24 weeks |
| Bordeaux |
| France |
| UP Clermont Ferrand | Clermont-Ferrand | France |
| Chu Grenoble | Grenoble | France |
| IPC Marseille | Marseille | France |
| CRLC de Nantes | Nantes | France |
| APHP Hopital Cochin | Paris | France |
| ONCOLOPE | Toulouse | France |
| 23000088 | Result | Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germa JR, O'Bryan-Tear CG, Haider T, Hoskin P. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013 Feb;63(2):189-97. doi: 10.1016/j.eururo.2012.09.008. Epub 2012 Sep 13. |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |